Exon 11 c-kit mutations are more closely correlated with a good prognosis in patients with gastrointestinal stromal tumour, who may benefit from lower doses of imatinib, whereas patients with exon 9 mutations may require higher doses (Debiec-Rychter et al, 2006). This evidence concerns the gene KIT and gastrointestinal stromal tumor.